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ABSTRACT: Androgens drive male secondary sexual differentia-
tion and maturation. Mutations in the androgen receptor (AR) gene
cause an array of abnormal sex differentiation phenotypes in humans,
ranging from mild through partial to complete androgen insensitivity.
Earlier, we reported a C3693T missense mutation in the AR gene in
a familial case of complete androgen insensitivity syndrome (CAIS),
resulting in the replacement of a highly conserved leucine residue with
phenylalanine (L859F) in ligand-binding domain (LBD) of the receptor.
In silico analysis and the information from the crystal structure of AR-
LBD indicated that the residue L859, located in helix 10 of AR protein,
plays a significant role in overall architecture of the ligand-binding
pocket. From this information we anticipated that the mutation might
have resulted in the loss of the ligand binding to the receptor. In the
present study, we have conducted the in vitro functional assays for this
mutation. The mutation resulted in highly significant loss of the ligand
binding to the receptor. The loss of ligand binding and subsequent AR
function was confirmed by the transactivation assay, in which we
observed very little activation of the reporter gene expressed under
the control of the ligand-AR complex.
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Androgens drive male secondary sexual differentia-tion and maturation. Two main androgens in
humans, testosterone (T) and dihydrotestosterone
(DHT), complex with the same receptor for their action
but confer different biological messages. The receptor-T
complex signals differentiation of the wolffian duct during
embryonic life, regulation of secretion of leutinizing
hormone by the hypothalamic-pituitary axis, and sper-
matognenesis. The receptor-DHT complex promotes
development of external genitalia and prostate during
embryogenesis and is also responsible for the changes that
occur at puberty in males (Haqq and Donahoe, 1998).
The AR gene mapped to Xq11.2-q12 encodes a protein
with 919 amino acids. The AR protein has a domain
organization consisting of N-terminal domain, DNA-
binding domain, and a C-terminal ligand-binding
domain (LBD). In addition to ligand binding, LBD is
also involved in nuclear localization, receptor dimeriza-
tion, and interaction with other proteins (Brinkmann et
al, 1989). Mutations in the AR gene are known to cause
complete androgen insensitivity syndrome (CAIS) rep-
resented by female phenotype, partial androgen in-
sensitivity syndrome (PAIS), with phenotype ranging
from predominantly male to female, and mild androgen
insensitivity syndrome (MAIS) characterized by under-
masculinization (Tsukada et al, 1994) or infertility in
otherwise healthy males (Rajender et al, 2007).
Hundreds of mutations have been reported in the AR
gene worldwide (Gottlieb et al, 2004). Most of these
studies are accompanied by functional assays to show
the mechanism of the pathogenesis of the mutation.
Various mutations in the AR gene have resulted either in
the loss of androgen binding to the receptor molecule or
loss in the transactivation potential of the ligand-AR
complex without significant loss in the ligand binding.
In our earlier report, we identified a C3693T (mRNA
position) missense mutation in the AR gene in a familial
case of CAIS. On the basis of the information from the
nature of the mutation and its location in the ligand-
binding pocket of the receptor molecule, we proposed
that the mutation might have resulted in the loss of the
ligand binding (Singh et al, 2006). We have now
conducted in vitro functional assays to prove the
mechanism of action of the mutation.
Subjects, Materials, and Methods
Subjects and Clinical History
The details of the subjects and the clinical record have been
provided in our earlier study (Singh et al, 2006). All the
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affected individuals in the family matched the clinical features
of CAIS. Direct DNA sequencing for the proband and other
affected individuals in the family resulted in the identification
of L859F mutation. The segregation of the mutation with the
disorder in this family indicated this mutation to underlie the
disorder. However, the functional significance of this mutation
in the pathogenesis of CAIS has now been elucidated by the
ligand binding and transactivation assays. This study was
approved by institutional ethical committee at CCMB.
Construction of the Mutant AR Clone
The AR clone (pSVARo) and the reporter clone (pMMTV-Luc)
were the kind gifts from Dr Bruce Gottlieb. We designed the
complimentary primers having the mutation in the middle of
forward and reverse primers. The 2 primer sequences were as
follows: forward: 59 GACGCTTCTACCAGTTCACCAAG
CTCCTG 39 (the mutated base is underlined); reverse: 59
CAGGAGCTTGGTGAACTGGTAGAAGCGTC 39 (the mu-
tated base is underlined). The whole plasmid molecule bearing
the AR clone was amplified using QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, Calif ) with the primers
bearing the desired mutation. The 50-mL polymerase chain
reaction (PCR) consisted of PCR buffer 5.0 mL, each primer
50 pmol, plasmid DNA 50 ng, deoxy nucleotide tri phosphates
(dNTPs) 1.0 mL, and PfuTurbo DNA polymerase 1.0 mL. The
reaction was set up under the following PCR conditions: 95uC
for 30 seconds followed by 16 cycles of denaturation at 95uC for
30 seconds, annealing at 55uC for 1 minute, and polymerization
at 68uC for 10 minutes with a final extension at 68uC for
10 minutes. The amplicon from the above reaction was in-
cubated at 37uC for 1 hour with DpnI restriction enzyme to
digest the wild-type (parental) plasmid molecules. Upon di-
gestion, the amplified product was checked on 1% agarose gel
for quantitative and qualitative analyses.
Bacterial Transformation and Plasmid Isolation (Miniprep)
The amplified product was used for the transformation in
Escherichia coli; 25 ng of the plasmid DNA was transformed
into E coli by heat shock at 42uC for 45 seconds. The ampicillin-
resistant colonies were picked up and used for plasmid isolation.
The plasmid DNA was isolated with the Mini prep kit
(Bangalore Genei, India) following the protocol provided by
the manufacturers. The DNA was dissolved in an appropriate
quantity of tris-EDTA (TE) buffer. After incubating at room
temperature for 2 hours, the plasmid DNA was checked on 2%
agarose gel for qualitative and quantitative evaluation.
Direct DNA Sequencing and Plasmid Isolation (Maxiprep)
The plasmid DNA (approximately 400 ng) was directly se-
quenced to confirm the presence of the mutation in the clone
using Big-Dye chain terminator cycle sequencing protocol on
3730 DNA analyzer (Applied Biosystems, Foster City, Calif )
(Thangaraj et al, 2003). The plasmid was isolated on a large scale
using the maxiprep kit (Qiagen Inc, Valencia, Calif) from the
mutant colonies following the protocol provided by the
manufacturers. The plasmid DNA was evaluated on 2% agarose
gel for quantitative and qualitative analyses.
Androgen-Binding Assay
About 800 ng of the plasmid DNA was used for transfection of
COS1 cells using 4.8 mL of lipofectamine (Stratagene, La Jolla,
Calif). After 72 hours of the transfection, the cells were washed
with PBS and medium replaced with a medium containing 5%
charcoal-stripped steroid-free serum. After 96 hours, the cells
were harvested using 0.01% trypsin–0.02% EDTA in phosphate-
buffered saline (PBS). The harvested cells were divided into 2
fractions for Western blotting and ligand-binging assays. The cells
were counted by using a hemocytometer to adjust the cell density.
Equal volumes of cell suspension with same cell density were
incubated with 0.5–2.0 nmol of methyltrienolone (R1881) in the
presence and absence of 1000-fold unlabeled methyltrienolone to
determine specific and nonspecific ligand binding, respectively.
After the incubation, the cells were washed with 2 mL of PBS 3
times to remove any unbound ligand. The cells were lysed with cell
lysis solution (50 mM Tris-Cl [pH 8.0], 10 mM EDTA [pH 8.0],
100 mM NaCl, 0.5% [vol/vol] Triton X-100, and 0.01 mL of
protease inhibitor mixture per mL [Sigma-Aldrich Corporation,
St Louis, Mo]). The whole cell lysate was then mixed with 6 mL of
scintillation counting fluid Bio-Safe II (Research Products
International Corp, Mount Prospect, Ill), and the disintegrations
per second were counted with the liquid scintillation analyzer
(1500 TRI-CARB; Packard, Downers Grove, Ill). The results
were expressed as binding sites per 105 cells.
Western Blotting
The harvested cells were lysed in the Laemmli buffer (50 mM
Tris with pH 6.8, 2% sodium dodecyl sulfate [SDS], 10%
glycerol, 5% b-mercaptoethanol, 0.01% bromophenol blue) and
boiled for 10 minutes in a water bath according to the method
of Laemmli (1970). The cell lysate was centrifuged at
10 000 rpm for 3 minutes (Biofuge pico, Heraeus Instruments,
Hanau, Germany) and supernatant collected. Protein content of
each lysate was estimated in the supernatant by Amido Black
method (Kaplan and Pedersen, 1985). Equal amounts of the
protein for different samples were loaded on SDS—poly-
acrylamide gel electrophoresis (SDS-PAGE) (10%) and electro-
phoresed at 80 V in running buffer (25 mM Tris, 250 mM
glycine, 1% SDS with pH 8.3). The resolved proteins were
electrophoretically transferred to a nitrocellulose membrane
(Hybond C, Amersham Life Sciences, Little Chalfont, United
Kingdom) following the semidry method of Towbin et al (1979).
Subsequently the membrane was stained with 0.1% Ponceau S
(prepared in 1% acetic acid) to check the efficiency of the
transfer. Before hybridization with the antibodies, the mem-
brane was washed with distilled water to remove the Ponceau
stain and blocked with 5% (wt/vol) nonfat milk in TBST
(150 mM NaCl, 20 mM Tris-HCl, 0.1% Tween 20, pH 7.6) for
2 hours at room temperature. Subsequently, the membrane was
washed and incubated with 1:10 000 dilution of primary
antibody in TBST. After 2 hours of incubation with the
primary antibody, the membrane was washed with TBST (3
times, 5 minutes each) and incubated with 1:1000 dilution of
alkaline phosphatase–conjugated secondary antibody in TBST.
After 1 hour of incubation, the membrane was washed with
TBST (3 times, 5 minutes each). Upon hybridization, the blot
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was incubated in alkaline phosphatase buffer (100 mM NaCl,
5 mM MgCl2, 100 mM Tris, pH 9.5) to which nitro-blue
tetrazolium chloride (NBT) (66 mL for 10 mL of buffer) and 5-
bromo-4-chloro-39-indolylphosphate p-toluidine (BCIP) salt
(33 mL for 10 mL buffer) were added. The blot was incubated
in the dark until a distinct band appeared.
Transactivation Assays
The cells were plated at a density of 2 6 105 in 6-well plates.
Upon 70% confluency stage, the cells were transfected with
300 ng of the mutant or normal AR clones along with 70 ng of
b-galactosidase (b-gal) and 430 ng of MMTV-Luc plasmids
using the protocol described above. After 24 hours, the
medium was replaced with a medium containing 5% char-
coal-stripped serum followed by the addition of the ligand
(0.5–2.0 nmol) to the medium. After 72 hours, the cells were
harvested by trypsinization and centrifugation. After washing
with PBS, the cells were counted by hemocytometer and
adjusted for the uniform cell density. The cells were lysed using
cell lysis solution (50 mM Tris-Cl [pH 8.0], 10 mM EDTA
[pH 8.0], 100 mM NaCl, 0.5% [vol/vol] Triton X-100, and
0.01 mL of protease inhibitor mixture per mL [Sigma]). The
activity of the cotransfected b-gal assay plasmid was measured
using b-gal assay kit (Roche, Palo Alto, Calif ) to estimate the
transfection efficiency. The luciferase activity was measured by
a luciferase assay system (Promega Corp, Madison, Wis) using
a TD-20/20 luminometer (Turner Design, Sunnyvale, Calif ).
Transfection efficiency was corrected by the ratio of the
luciferase activity to b-gal activity.
Results
Site-directed mutagenesis resulted in the successful in-
corporation of the mutation C3693T in AR clone. The
presence of the mutation in the clone was confirmed by its
sequencing in forward and reverse directions. Protein
isolation followed by Western blotting and hybridization
confirmed the expression of both the wild-type and the
mutant proteins (Figure 1). Ligand-binding assay showed
negligible binding of R1881 to the mutant receptor in
comparison with the wild type under all concentrations of
the ligand used (Figure 2). Complementing the results of
binding assay, the transactivation assay showed very less
activation of the reporter gene in the mutant receptor in
comparison with the wild-type receptor (Figure 3).
Discussion
Our earlier study on a familial case of CAIS revealed
C3693T mutation in exon 7 of the AR gene, leading to
Figure 1. Western blotting. Western blotting showed normal
expression of the androgen receptor (AR) protein in the cells
transfected with wild-type and mutant clones.
Figure 2. Ligand-binding assay. The ligand-binding assay showed
a drastic decrease in the binding of R1881 to the mutant receptor in
comparison with the wild-type receptor. Radiolabeled R1881 and
unlabeled R1881 were used to determine the specific and non-
specific ligand binding, respectively. nonspecific binding-wild type
(NSB-WT) shows the nonspecific ligand binding to the wild-type
receptor, and nonspecific binding-mutant type (NSB-MT) shows the
nonspecific binding to the mutant receptor.
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replacement of leucine with phenylalanine at codon 859
of AR (Singh et al, 2006). L859 is a part of AR-LBD, and
highly conserved across diverse species (Singh et al, 2006).
The importance of this amino acid residue in AR function
is further strengthened by its critical location in the
ligand-binding pocket of the receptor molecule. In the
previous study, we hypothesized that the ligand-binding
pocket in the mutant receptor is unable to attain proper
conformation, resulting in total disruption of ligand
binding and hence CAIS. In the present study, we have
functionally proved that it is the highly significant loss of
ligand binding that resulted in the disorder in this family.
The in vitro assays revealed that the androgen binding
was reduced to negligible levels as a result of the
mutation. This could be due to the fact that the mutated
amino acid localized to LBD. However, the observation
of no transactivation in the mutant receptor must be due
to the loss of complex formation between androgen and
AR protein. The AR protein normally forms complex
with the androgen and localizes to the nucleus.
However, the absence of ligand or failure of ligand
binding to the receptor results in the cytoplasmic
localization of the receptor with perinuclear distribu-
tion, enforcing its faster degradation (Kemppainen et al,
1992). Therefore, the mutations resulting in complete
loss of androgen binding should result in failure of
nuclear localization of the AR protein, resulting in rapid
degradation. Similarly, the complete loss of androgen
binding as a result of L859F mutation in the present case
would have rendered the AR protein nonfunctional
along with its rapid degradation as a result of
cytoplasmic localization.
Most of the reported mutations associated with
androgen insensitivity syndrome localize to LBD and
are available at the androgen receptor mutation
database along with resulting phenotypes (Gottlieb et
al, 2004). The mechanism of pathogenesis of most of
these mutations is well supported by the functional
assays. The mutations resulting in the replacement of
the amino acids by similar other amino acids should
result in partial loss of function, whereas the replace-
ment of an amino acid by a dissimilar amino acid should
result in complete loss of function. However, this did not
hold true when we compared the nature of amino acid
substitution with the extent of androgen insensitivity for
the mutations reported in exon 7 to date (available at the
AR mutation database) (Gottlieb et al, 2004). Exon 7 is
the second highly mutated region of the AR gene after
exon 5. More than 37 different types of mutations have
been reported in 127 individuals (Gottlieb et al, 2004).
Of these mutations, the most (20 mutations) were
reported in CAIS cases, followed by PAIS (11 muta-
tions), CAIS and PAIS (4 mutations), MAIS (1
mutation), and prostate cancer (1 mutation). Many
mutations replacing a highly dissimilar amino acid
resulted in PAIS and did not alter the ligand binding,
whereas many other mutations replacing a similar
amino acid without significantly altering ligand binding
resulted in CAIS. Likewise, the mutation under study
resulted in the replacement of a hydrophobic amino acid
with another hydrophobic amino acid but resulted in
CAIS. However, unlike other mutations, we observed
complete loss of ligand binding. The above discussion
shows that the ultimate phenotype in AR mutations
does not depend upon the kind of amino acids replaced
but on the extent of the conservation of that particular
amino acid and its location in the 3-dimensional crystal
structure of the protein.
Mutations in the AR gene are known to show
phenotypic variation in different individuals. Substan-
tial variations have been noted in the familial cases
bearing the same mutation. Somatic mutations in the
androgen target tissues have been proposed to contrib-
ute to phenotypic variation. However, somatic muta-
tions have been able to explain the phenomenon only in
a few cases of the more than 25 cases of phenotypic
variation reported to date (Gottlieb et al, 2001a,b). All
the patients in the present family exhibited same
phenotype; however, the phenotypic variation associat-
ed with this mutation cannot be ruled out in further
generations if somatic mutations in the androgen-
responsive tissues result in the back mutation. Certain
mutations in the AR gene are even known to result in
a gradient of the phenotypes in different affected
individuals. However, this is the first report of the
L859F mutation; therefore, phenotypic variations asso-
Figure 3. Transactivation assay. Transactivation assay was done to
check the activity of the ligand-receptor complex in the wild-type and
mutant receptors. The activity of the luciferase enzyme expressed
under the control of ligand–androgen receptor complex responsive
promoter was measured as a function of transactivation. The assay
showed negligible transactivation in the mutant receptor in compar-
ison with the wild-type receptor.
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ciated with this mutation have to wait for more studies
reporting the same mutation.
The patients were given estrogen therapy and un-
derwent surgery to construct the female genital organs.
We are in communication with the patients to provide
genetic counseling for future pregnancies of their
healthy siblings to abandon the transmission of the
mutated X chromosome to the coming generations.
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